Author

Daniel A. Morgenstern

University of TorontoORCID 0000-0002-4859-1108Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:whole-genome sequencing· 1 Organism:zebrafish· 1

Frequent Co-Authors

Adam ShlieniD· 1 shared Alex Weiss· 1 shared Amy Y. PaniD· 1 shared Andrew McFadyeniD· 1 shared Anisha Rajaselvam· 1 shared Anita VillaniiD· 1 shared Ashish R. DeshwariD· 1 shared Brian Thomas KalishiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam ShlienORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Generalizable, Governance-Embedded Pathway for Assessing Patient-Level Opportunities for Genetic Medicines

David Cheerie, Amy Y. Pan, Meryl Acker, Kimberly Amburgey, Jashanpreet Sidhu, Laura Buckley, Hernan Dario Gonorazky, Nicole K. McKinnon, Lyndsey McRae, Miriam S. Reuter, Lindsey M. Vogt, Laura A Zahavich, Tomasz L. Czarny, Eriskay Liston, Andrew McFadyen, , Gregory Costain

The paper describes a structured initiative to assess patient eligibility for genetic medicines, showing high uptake and feasibility of a multidisciplinary approach.

medRxiv · Sep 23, 2026 · PreprintGenetic & Genomic Medicine

DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR Inhibition

Madeline N. Hayes, Sarah Cohen‐Gogo, Lynn Kee, Xueting Xiong, Alex Weiss, Mehdi Layeghifard, Yagnesh Ladumor, Ivette Valencia-Sama, Anisha Rajaselvam, David R. Kaplan, Anita Villani, Adam Shlien, Daniel A. Morgenstern, Meredith S. Irwin

This study shows DDR gene mutations enhance neuroblastoma progression and sensitivity to PARP + ATR inhibitors in zebrafish models and human cells.

Cell Reports · Apr 1, 2025Peer-reviewedCancer Biology